Top Railroad Stocks To Buy Right Now

On this day in economic and business history...

The golden spike sank into the earth at Promontory Summit in Utah on May 10, 1869. The Transcontinental Railroad was complete, joining the east and west of a sprawling 3,000-mile wide nation. Two railroad enterprises, the Union Pacific (NYSE: UNP  ) and the Central Pacific, had been built at a frenzied pace since shortly after President Abraham Lincoln's signature approved federal funds for construction in 1862. Both railroads were created to service this legislation, with Union Pacific building west from the Missouri River as the Central Pacific�struck out east from Sacramento.

The 1,900-mile line, built in only six years, was, as Howard Means writes in Money and Power: the History of Business:

... the Apollo Project of the 19th century -- one of those rare moments in history when discovery and technology seems to be colliding with destiny. National pride was at stake, and national aspiration, and something bigger still: Just as the manned landing on the moon would do, the railroad conquered an unknown world, planted a first tentative foot in an unknown space. Only those present could see the final spike of iron, clad in silver and gold, being driven into the last link of rail ... but the event was broadcast by telegraph and followed by Americans as avidly -- and greeted as enthusiastically -- as Neil Armstrong's lunar 'giant leap for mankind' almost exactly 100 years later, on July 20, 1969.

Top Railroad Stocks To Buy Right Now: Cornerstone Progressive Return Fund(CFP)

Cornerstone Progressive Return Fund is a closed-ended equity fund of fund launched and managed by Cornerstone Advisors, Inc. The fund invests funds investing in the public equity markets of the United States. It invests in stocks of companies operating across diversified sectors. Cornerstone Progressive Return Fund was formed on April 26, 2007 and is domiciled in the United States.

Advisors' Opinion:

• [By Dan Caplinger]

  But you can see in several places the consequences of the stampede toward high yield. Here are just a few:

  Closed-end funds Cornerstone Progressive (NYSEMKT: CFP  ) and Pimco High Income (NYSE: PHK  ) both make fixed payments back to fund shareholders on a monthly basis, and their distribution yields are truly extraordinary, at about 17% and 12%, respectively. Those dividends have enticed shareholders to pay $1.30 to $1.40 or more for each $1 of assets in the funds. Yet during most months, a substantial portion of those distribution payments has simply been a return of investor capital rather than true income from the funds' investments. A recent study discussed in The Wall Street Journal found that returns on a portfolio with a combined value and dividend-income strategy outperformed a strategy focused more exclusively on maximizing dividends by an average of 1.7 percentage points per year, a huge edge in long-run returns. In the dividend ETF arena, most funds tend to focus on maximizing yield. Although the popular Vanguard Dividend Appreciation (NYSEMKT: VIG  ) ETF bucks the trend by screening first for consistent dividend growth and only then looking at yield as a factor, many rival ETFs start with high-yielding stocks as their baseline and only then consider other desirable traits. Others focus solely on high-dividend niches of the market, such as iShares FTSE NAREIT Mortgage-Plus (NYSEMKT: REM  ) and its concentration on high-yield mortgage REITs.

  When dividend stocks get too popular, their prices get out of line with both their dividend income and the fundamentals of the businesses that underlie those stocks. In simpler terms, when dividend stocks become bad values, it's time to consider looking elsewhere for a margin of safety.

Top Railroad Stocks To Buy Right Now: Latteno Food Corp (LATF)

Latteno Food Corp. (Latteno), incorporated on August 24, 1994, is engaged in acquiring, organizing, developing and upgrading companies in the international food and beverage market. Latteno is specializing in the dairy industry and coffee industry. The Company operates through its subsidiary in Brazil. On February 10, 2010 Latteno acquired Global Milk Businesses and Administration of Private Properties Ltda. (Global Milk). Global Milk holds the rights of certain intellectual property of the brand name products manufactured and sold under the brand name Teixeira. In March 2013, the Company acquired Green Cannabis Collective Inc.

Latteno is leasing an instant and roasted coffee factory located in Cruzeiro, Sao-Paulo, which was property the Company previously owned under its BDFC Brasil Alimentos Ltda (BDFC) subsidiary. In addition to the lease, the Company has maintained ownership of four brand names, Samba Cafe, Vivenda, Torino and Brazilian Best, used in the past by Latteno to sell its instant and roasted coffee across the world. The Company engaged the service companies to assist with its operations, such as Log-Frio Ltda, SigaSolutions Ltda, Microsiga Ltda and Varistao Transportes Ltda.

The Company competes with Nestle, Companhia Cacique de Cafe Soluvel, Cafe Soluvel Brasilia and Companhia lguacu de Cafe Soluvel.

Advisors' Opinion:

• [By James E. Brumley]

  What do you get when you cross a Coffee Holding Co., Inc. (NASDAQ:JVA) with a Medical Marijuana Inc. (OTCMKTS:MJNA) and a Kraft Foods Group Inc. (NASDAQ:KRFT)? No, it's not a setup for a punch line - there's a legitimate answer. And that answer is, Latteno Food Corp. (OTCMKTS:LATF).

• [By James E. Brumley]

  A week and a half ago when I suggested Latteno Food Corp. (OTCMKTS:LATF) was an effective way of getting into the medical marijuana craze for anyone who missed the big runups (the first or the second time) from names like Medical Marijuana Inc. (OTCMKTS:MJNA) or Hemp, Inc. (OTCMKTS:HEMP), not many people agreed with my assessment. That's the nice way of saying I received some "colorful counter-opinions" to my bullishness on LATF. Indeed, some readers were downright enraged I would dare compare the company to stocks like MJNA or HEMP, citing reasons ranging from the possibility that it's a complete scam to the possibility that the capital structure as amazingly unfair to current shareholders.

• [By James E. Brumley]

  What do you get when you cross a Coffee Holding Co., Inc. (NASDAQ:JVA) with a Medical Marijuana Inc. (OTCMKTS:MJNA) and a Kraft Foods Group Inc. (NASDAQ:KRFT)? No, it's not a setup for a punch line - there's a legitimate answer. And that answer is, Latteno Food Corp. (OTCMKTS:LATF).

Hot Recreation Companies To Invest In Right Now: Winning Brands Corp (WNBD)

Winning Brands Corporation is a manufacturer of cleaning solutions. The Company offers products in three markets: Consumer, Industrial and Commercial. Its Consumer products include 1000+ Stain Remover; KIND Laundry Detergent; KIND Fabric Softener; KIND Laundry Stain Remover, and CLEAN1 All Purpose. Its Industrial products include TrackMoist Dust Suppressant, and ReGuard-4 Equipment Cleaning for Emergency Responders. Its Commercial products include Professional Wet Cleaning Solutions. The Company owns 100% interests in Niagara Mist Marketing Ltd.

The consumer products are offered for sale through stores in various sectors, such as hardware, paint, convenience, and grocery. The industrial products are targeted for sale through professional property maintenance personnel in the case of TrackMoist and distributors to fire-fighting organizations in the case of ReGuard-4. The commercial products are for use by businesses in their line of work to generate a finished product, with an emphasis on the dry-cleaning sector, such as on cruise ships to perform cleaning of Dry Clean Only garments in substitution of the solvent perchloroethylene (Perc).

Advisors' Opinion:

• [By Peter Graham]

  Small cap stocks Beamz Interactive Inc (OTCBB: BZIC), EHouse Global (OTCBB: EHOS) and Winning Brands Corporation (OTCMKTS: WNBD) were all heading in different directions at the end of last week with the first small cap surging 49.94% while the other two sank 31.28% and 25.32%, respectively, on Friday. Moreover, all three small cap stocks are already heading in different directions again this morning. So where should investors and traders place their bets? Here is a closer look at all three small cap stocks:

Top Railroad Stocks To Buy Right Now: Sarepta Therapeutics Inc (SRPT)

Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.

The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.

Duchenne Muscular Dystrophy Program

The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.

Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.

Anti-Viral Programs

The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.

The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.

The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.

AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.

Influenza Program

The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.

The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.

The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.

Advisors' Opinion:

• [By Brian Orelli]

  After Sarepta Therapeutics (NASDAQ: SRPT  ) announced that it was going to have a conference call today to update investors about its plans for a marketing application with the Food and Drug Administration, I joked on Twitter that the lede for my article, "I couldn't have predicted this," worked either way.

• [By Keith Speights]

  The words of the great big-band leader Duke Ellington came to mind after hearing the first quarter results from Sarepta Therapeutics (NASDAQ: SRPT  ) : "It don't mean a thing." �Here are the highlights from those results -- and why they're practically meaningless.

Top Railroad Stocks To Buy Right Now: Google Inc.(GOOG)

Google Inc. maintains an index of Web sites and other online content for users, advertisers, and Google network members and other content providers. It offers AdWords, an auction-based advertising program; AdSense program, which enables Web sites that are part of the Google Network to deliver ads from its AdWords advertisers; Google Display, a display advertising network that comprises the videos, text, images, and other interactive ads; DoubleClick Ad Exchange, a real-time auction marketplace for the trading of display ad space; and YouTube that provides video, interactive, and other ad formats for advertisers. The company also provides Google Mobile that optimizes Google?s applications for mobile devices in browser and downloadable form; and enables advertisers to run search ad campaigns on mobile devices, as well as Google Local that provides local information on the Web; and Google Boost for small businesses to participate in the ads auction. In addition, it offers And roid, an open source mobile software platform; Google Chrome OS, an open source operating system; Google Chrome, a Web browser; Google TV, a platform for the consumers to use the television and the Internet on a single screen; and Google Books platform to discover, search, and consume content from printed books online. Further, the company provides Google Apps, a cloud computing suite of message and collaboration tools, which includes Gmail, Google Docs, Google Calendar, and Google Sites; Google Search Appliance that offers real-time search of business and intranet applications, and public Web sites; Google Site Search, a custom search engine; Google Commerce Search for online retail enterprises; Google Checkout to make online shopping and payments streamlined and secure; Google Maps Application Programming Interface; and Google Earth Enterprise, a firewall software solution for imagery and data visualization. Google Inc. was founded in 1998 and is headquartered in Mountain View, California.

Advisors' Opinion:

• [By Associated Press]

  LOS ANGELES (AP) --�Google's (NASDAQ: GOOG  ) new music service offers a lot of eye candy to go with the tunes. The song selection of around 18 million tracks is comparable to popular services such as Spotify and Rhapsody, and a myriad of playlists curated along different genres provides a big playground for music lovers.

• [By Dan Burrows]

  Meanwhile, PC sales are a melting iceberg, and nothing is going to change that. MSFT stock is never going to get a boost from the tablets that are replacing PCs, because even if it had the best hardware and software, the market has already gone to Apple (AAPL) and anyone running Google’s (GOOG) Android operating system.

Top Railroad Stocks To Buy Right Now: Vermilion Energy Inc (VET)

Vermilion Energy Inc. (Vermilion), is engaged in the business of oil and natural gas exploitation, development, acquisition and production in Australia, Canada, France, Ireland and the Netherlands. As of December 31, 2011, Vermilion holds an average working interest of 68.5% in 395,616 (271,067 net) acres of developed land, 582 (396 net) producing natural gas wells and 319 (198 net) producing oil wells in Canada. Vermilion holds an 83.6% working interest in 193,017 acres of developed land in the Aquitaine and Paris Basins. Vermilion's Netherlands assets consist of eight onshore concessions and one offshore concession located in the northern part of the country. In October 2013, Vermilion Energy Inc, through its wholly owned subsidiary acquired Northern Petroleum Nederland B.V. Advisors' Opinion:

• [By Marc Bastow]

  Oil exploration and production company Vermillion Energy (VET) raised its monthly dividend 7.5% to 21.50 cents (Canadian) per share, and is expected to be payable on February 17.
  VTE Dividend Yield: 1.52%